6 Endocrinology Headlines You Missed in February 2026

Endocrinology began picking up steam in February, with several key approvals from the US Food and Drug Administration (FDA) and multiple key trial results being announced. The momentum from last month promises more news to come as we begin to round out the first quarter of 2026.

As we enter March, which looks to be a busy month for endocrinology, the HCPLive editorial team has collected 6 of the most impactful headlines of February 2026 – catch up on any news you may have missed below.

FDA News

FDA Approves 3 New Pediatric Indications for Once-Weekly Somapacitan-beco (Sogroya)

On February 27, the FDA approved 3 new indications for once-weekly somapacitan-beco (Sogroya) 5 mg, 10 mg, and 15 mg injections for pediatric patients with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age, and growth hormone deficiency. This indication opened the drug’s accessibility to children ≥2.5 years of age, taking the form of a once-weekly treatment.

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

On February 25, 2026, the FDA approved ET-600 under the name Desmoda for the treatment of central diabetes insipidus in pediatric patients. ET-600 is now the first and only FDA-approved oral liquid formulation of desmopressin following this decision. The approval was based in large part on results from a bioequivalence study completed in March of 2025.

Trial Results

ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D

On February 26, 2026, Eli Lilly announced detailed results from the ACHIEVE-3 trial, highlighting the results of orforglipron’s head-to-head comparison with semaglutide in patients with type 2 diabetes (T2D). Orforglipron demonstrated improvements in A1c, weight loss, non-HDL and HDL cholesterol, total cholesterol, blood pressure, and triglycerides. Additionally, this dose of orforglipron is not required to be taken with food or water.

VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D

Parent company Pfizer announced the results of their VESPER-3 phase 2b trial on February 3, 2026, which highlighted their investigative long-term GLP-1 PF’3944’s superiority to placebo in weight reduction in . The trial’s 2 primary endpoints – demonstrating efficacy in achieving continued weight loss after switching from weekly to monthly dosing and demonstrating PF’3944’s capacity to switch to a 4-fold equivalent monthly dose safely – were both met. Full data from VESPER-3 will be presented at the American Diabetes Association Scientific Sessions on June 6, 2026.

Podcast Updates

Diabetes Dialogue: Launch of the Zepbound KwikPen

In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking release of Eli Lilly’s Zepbound KwikPen. This multi-dose device, available now through LillyDirect, consolidates the traditional 4 single-use pens per month into 1 pen with 4 injections included. This allows for safer dose adjustment than prior vial formulations, as the latter did not include preservatives and were not intended for repeat punctures.

Diabetes Dialogue: Implantable Insulin Pumps and Interoperability

In this episode, Isaacs and Bellini discuss the new implantable insulin pump from Portal Diabetes, which has been granted Breakthrough Device designation from the FDA. The device delivers insulin intraperitoneally, which allows for rapid absorption into the portal circulation. This mechanism allows for the elimination of pre-meal bolusing and may potentially improve exercise safety due to shorter insulin tail effects.